FDA approves Teva antibiotic
JERUSALEM — The Food and Drug Administration has approved a new generic drug from Teva Pharmaceutical Industries for treating eye infections, the company said.
The Israeli drug maker announced the approval of the antibiotic drug tobramycin inhalation solution, a generic version of Novartis’ Tobi.
Tobi has sales of about $350 million during the 12-month period that ended in June, according to IMS Health.
Diplomat receives ASHP accreditation for post-graduate residency program
FLINT, Mich. — The American Society of Health System Pharmacists has granted accreditation to a post-graduate program offered by specialty pharmacy Diplomat, the company said.
Diplomat, which recently shortened its name from Diplomat Specialty Pharmacy, received ASHP accreditation for its postgraduate year one, or PGY1 pharmacy residency program.
"Our PGY1 pharmacy residency program, with a focus on specialty pharmacy, was established in 2011 as part of Diplomat’s training programs offered through Diplomat University," PGY1 program director Jennifer Hagerman said. "To receive the maximum length of accreditation from ASHP is a reflection of the resources Diplomat has committed to be a premier training institute for professionals within the specialty pharmacy industry, as well as the commitment of those involved in the program."
Before it implemented the PGY1 pharmacy residency program, the company had an accredited PGY1 community residency program, from 2007 to 2010. The current program takes place at Diplomat’s Flint, Mich., headquarters, lasts one year and emphasizes the development of advanced clinical skills within a specialty pharmacy setting. Residents also gain experience within ambulatory care and community settings, engaging in all aspects of pharmacy practice, including advanced-level clinical, operational and business activities. Residents also have the opportunity to complete a teaching certificate program through Ferris State University College of Pharmacy.
Onco360, MedImpact sign cancer-treatment deal
NEW YORK — Cancer-focused specialty pharmacy Onco360 has signed a contract with privately owned pharmacy benefit manager MedImpact Healthcare Systems, whereby the pharmacy will offer its services to the PBM’s members.
The two companies said the partnership would offer MedImpact clients "a unique and effective solution for bending the cost curve," and was aimed at providing benefit payers with a proven and effective cancer pharmacy program that combines a cost-effective dispensing model with "clinical excellence."
"This is an exciting and timely collaboration, as the healthcare industry is at a crossroads, and the complexities of cancer care demand a novel solution," Onco360 CEO Burt Zweigenhaft said. "By addressing three key facets — fragmentation, coordination of care and cost control — we believe this comprehensive solution can have a positive effect for not just payers, but more importantly, the patients we put at the center of everything we do."
MedImpact president Greg Watanabe noted that the cost of cancer care was projected to increase to nearly $175 billion by 2020, a fourfold increase in less than a decade. The collaboration will bring the multidisciplinary approach used in many cancer treatment centers to the outpatient setting, featuring board-certified oncology pharmacists to provide coordination and clinical experience throughout the entire continuum of cancer care.
"Bringing together the oncology experience and expertise of Onco360 with the MedImpact approach to pharmacy benefit management will result in a unique and integrated benefit solution for oncology," Watanabe said. "With the coming changes of the Affordable Care Act and the heightened focus on delivering quality measures, it is clear to MedImpact and our clients that something needs to be done to more effectively manage the treatment and cost of cancer care."